

EM Intressenter AB initiates compulsory redemption proceedings

EM Intressenter AB ("**EM Intressenter**"), holding approximately 94.3 percent of the shares and approximately 83.6 percent of the votes in Elos Medtech ("**Elos Medtech**" or the "**Company**"), has today initiated compulsory redemption of the remaining shares in Elos Medtech. Elos Medtech will notify the minority shareholders that compulsory redemption has been requested and that the minority shareholders will have the opportunity to, no later than two weeks from the date of the notification, in writing report that they wish to bring their own action and state a joint arbitrator. If shareholders to which the redemption claim is directed do not submit the name of a joint arbitrator within the prescribed time, the Board of Directors of Elos Medtech will file an application with the Swedish Companies Registration Office for the appointment of a trustee. The trustee shall appoint a joint arbitrator for the minority shareholders and shall safeguard the interest of absent shareholders in the dispute.

For further information, please contact:

Stefano Alfonsi, President and CEO, +44 772 04 98 342, email: stefano.alfonsi@elosmedtech.com
Magnus René, Chairman of the Board, +1 781 266 6957, email: magnus.rene@mareadvisory.com

About Elos Medtech

Elos Medtech is a leading development and production partner for medical devices and components, with a focus on dental and orthopedic implants and instruments. The Company operates from facilities in Sweden, Denmark, China, and the U.S. The customer base comprises international medical technology companies.

Elos Medtech has more than 650 employees and a turnover of approximately SEK 950 million. Elos Medtech has been listed on NASDAQ Stockholm AB since 1989. Elos Medtech's B share is categorized as a Health Care company on the Mid Cap list.

This is information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on November 21st, 2023, at 19:30 (CET).